Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the
efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the
scalp.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Pharma Global FZE Sun Pharmaceutical Industries Limited